Estrogen suppresses melatonin-enhanced hyperactivation of hamster spermatozoa

Masakatsu Fujinoki* and Gen L. Takei

Department of Physiology, Dokkyo Medical University, Mibu, Tochigi 321-0293, Japan

*Please address correspondence to:
Masakatsu Fujinoki
Department of Physiology, School of Medicine, Dokkyo Medical University, Mibu,
Tochigi 321-0293, Japan
Tel: +81-282-87-2124
Fax: +81-282-86-7835
E-mail: fujinoki@dokkyomed.ac.jp

Short title: Interaction of melatonin and 17βE₂

Key words: Estradiol, Hyperactivation, Melatonin, Non-genomic regulation, Spermatozoa
Abstract

Hamster sperm hyperactivation is enhanced by progesterone, and this progesterone-enhanced hyperactivation is suppressed by 17β-estradiol (17βE₂) and γ-aminobutyric acid (GABA). Although it has been indicated that melatonin also enhances hyperactivation, it is unknown whether melatonin-enhanced hyperactivation is also suppressed by 17βE₂ and GABA. In the present study, melatonin-enhanced hyperactivation was significantly suppressed by 17βE₂ but not by GABA. Moreover, suppression of melatonin-enhanced hyperactivation by 17βE₂ occurred through non-genomic regulation via the estrogen receptor (ER). These results suggest that enhancement of hyperactivation is regulated by melatonin and 17βE₂ through non-genomic regulation.
Introduction

In mammals, only capacitated spermatozoa can fertilize an egg. Capacitated spermatozoa generally show two major responses, known as “acrosome reaction” and “hyperactivation” [1, 2, 3]. The acrosome reaction is an exocytosis occurring at the sperm head; and is required for penetration of the zona pellucida (ZP) [1]. Hyperactivation is a modification of flagellar movement to create the driving force for penetrating the ZP [1, 2, 3]. Moreover, the ability of spermatozoa to be hyperactivated correlates with the success of in vitro fertilization [4].

It has been recently reported that hyperactivation is regulated by several hormones and transmitters (e.g., progesterone [5-10], 17β-estradiol (17βE2) [8, 10], melatonin [11, 12], serotonin (5-HT) [13] and γ-aminobutyric acid (GABA) [14-18]). In the hamster, progesterone, melatonin and serotonin enhance hyperactivation in a dose-dependent manner [7, 10, 11, 13]. Moreover, progesterone enhances hyperactivation through non-genomic regulation associated with a progesterone receptor (PR), phospholipase C (PLC), inositol 1,4,5-tris-phosphate receptor (IP3R), protein kinases and tyrosine phosphorylations [7, 9]. Melatonin enhances hyperactivation via melatonin receptor type 1 (MT1) [11]. Serotonin enhances hyperactivation via the 5-HT2 and 5-HT4 receptors [13]. In humans, progesterone and melatonin change motility parameters and enhance hyperactivation [5, 6, 12]. It has also been shown that 17βE2 and GABA dose-dependently suppress progesterone-enhanced hyperactivation in the hamster [8, 9, 18]. Furthermore, 17βE2 suppresses progesterone-enhanced hyperactivation through non-genomic regulation associated with the estrogen receptor (ER) and tyrosine dephosphorylations [8]. GABA suppresses progesterone-enhanced hyperactivation via the GABA_A receptor [18]. Interestingly, in humans, rams and rats, GABA increases
hyperactivation via the GABA_A receptor [14-17].

In hamster spermatozoa, there are three enhancers of hyperactivation: progesterone [7, 9, 10], melatonin [11] and serotonin [13]. Moreover, there are two suppressors of progesterone-enhanced hyperactivation: 17βE_2 [8, 10] and GABA [18]. In order to understand the regulatory mechanisms of sperm hyperactivation caused by enhancers and suppressors, interactions among them need to be examined. Therefore, in the present study, we examined whether melatonin-enhanced hyperactivation of hamster spermatozoa is suppressed by 17βE_2 and GABA.

**Materials and Methods**

**Chemicals**

Hypotaurine, (-)epinephrine, 17α-estradiol (17αE_2), 17βE_2, fluorescein isothiocyanate and bovine serum albumin (BSA)-conjugated 17βE_2 (BSA-17βE_2), GABA, melatonin, sodium taurocholate, sodium metabisulfite, and tamoxifen were purchased from Sigma-Aldrich (St Louis, MO, USA). BSA fraction V was purchased from Merck KGaA (Darmstadt, Germany). Other reagent-grade chemicals were purchased from Wako Pure Chemical Industries (Osaka, Japan).

**Animals and preparation of hyperactivated spermatozoa**

Spermatozoa were obtained from the posterior epididymis of sexually mature male golden hamsters (*Mesocricetus auratus*). The experimental plan was approved by the Animal Care and Use Committee of the Dokkyo Medical University (Experimental permission number: 0107), and the experiment was carried out according to the Guidelines for Animal Experimentation of the University.
Hyperactivated spermatozoa were prepared using the modified Tyrode’s albumin lactate pyruvate (mTALP) medium [20] containing 101.02 mM NaCl, 2.68 mM KCl, 2 mM CaCl$_2$-2H$_2$O, 1.5 mM MgCl$_2$-6H$_2$O, 360 µM NaH$_2$PO$_4$-2H$_2$O, 35.70 mM NaHCO$_3$, 4.5 mM D-glucose, 90 µM sodium pyruvate, 9 mM sodium lactate, 500 µM hypotaurine, 50 µM (-)epinephrine, 200 µM sodium taurocholate, 5.26 µM sodium metabisulfite, 0.05% (w/v) streptomycin sulfate, 0.05% (w/v) potassium penicillin G and 15 mg/ml BSA (pH 7.4 at 37 C under 5% (v/v) CO$_2$ in air) according to the method described previously [19]. A drop (~ 5 µl) of posterior epididymal spermatozoa was placed in a culture dish (diameter, 35 mm) with 3 ml of the mTALP medium, followed by incubation at 37 C for 5 min to allow spermatozoa to swim up. All of the mTALP medium containing motile spermatozoa was placed in a new culture dish and incubated for 4 h at 37 C under 5% (v/v) CO$_2$ in air to allow hyperactivation to occur. As stock solutions, melatonin (1 µM), 17αE$_2$ (20 µg/ml) and 17βE$_2$ (20 µg/ml) were dissolved in ethanol; tamoxifen was dissolved at 1 mM in dimethyl sulfoxide; and GABA (5 mM) and BSA-E$_2$ (7.4 µM) were dissolved in pure water. GABA, 17αE$_2$, 17βE$_2$, tamoxifen or vehicle was added to the mTALP medium after swim up, and after 5 min of incubation, melatonin or vehicle was added to the mTALP medium (Figs. 1, 2, 3A, 3B, 5A, 5B). Tamoxifen or vehicle was added to the mTALP medium after swim up, and after 5 min incubation, 17βE$_2$, BSA-17E$_2$ or vehicle was added to the mTALP medium again. After additional incubation for 5 min, melatonin or vehicle was added to the mTALP medium (Figs. 3C, 3D, 4). Mixtures of 17βE$_2$ and melatonin or vehicle were added to the mTALP medium after swim up (Figs. 5C, 5D). Melatonin or vehicle was added to the mTALP medium after swim up, and after 5 min of incubation, 17βE$_2$ or vehicle was added to the mTALP medium (Figs. 5E, 5F). In all experiments, the
maximal concentration of vehicle was 0.3% by volume.

Measurement of the percentage of hyperactivated spermatozoa

The percentage of hyperactivated spermatozoa was measured according to the method described previously [19]. Motile spermatozoa were recorded on videotape using a phase-contrast illumination unit attached to a microscope (IX70, Olympus Corp., Tokyo, Japan) with a CCD camera (Progressive 3CCD, Sony Corp., Tokyo, Japan) and a small CO₂ incubator (MI-IBC, Olympus). Each observation was performed at 37°C, recorded for 2 min, and analyzed by slow-motion playback and manual counting of the numbers of total spermatozoa and hyperactivated spermatozoa in four different fields per point of analysis. The analysis was done in a blinded manner. Motile spermatozoa that exhibited asymmetric and whiplash flagellar movement and a circular and/or octagonal swimming locus were defined as hyperactivated [3, 21]. The percentage of motile spermatozoa was defined as the number of motile spermatozoa / total number of spermatozoa × 100 (%). The percentage of hyperactivated spermatozoa was defined as the number of hyperactivated spermatozoa / total number of spermatozoa × 100 (%). One hamster was used per experiment, and experiments were repeated four times.

Statistical analysis

Data are expressed as the mean ± standard deviation (SD). Statistical analysis was carried out using Tukey’s test of analysis of variance. $P < 0.05$ was considered significantly different.
**Results**

*Effects of 17βE₂ and GABA on melatonin-enhanced hyperactivation*

We examined whether melatonin-enhanced hyperactivation is suppressed by 17βE₂ and GABA in a manner similar to progesterone-enhanced hyperactivation [8, 18]. After swim up, 20 ng/ml 17βE₂ or 5 µM GABA was added to the mTALP medium containing motile spermatozoa, and after additional incubation for 5 min, 1 nM melatonin was added to the same medium. After supplementation with 1 nM melatonin, spermatozoa were incubated for 4 h in order to induce hyperactivation. As shown in Fig. 1A, the percentage of motile spermatozoa was not affected by addition of 1 nM melatonin and 20 ng/ml 17βE₂ when spermatozoa were exposed to 1 nM melatonin after exposure to 17βE₂. In contrast, as shown in Fig. 1B, melatonin-enhanced hyperactivation was significantly suppressed by 20 ng/ml 17βE₂.

After incubation for 1 or 1.5 h, melatonin-enhanced hyperactivation was significantly suppressed by 17βE₂ (1 h, Melatonin: 17.4% ± 3.17, 17βE₂ → Melatonin: 10.67% ± 2.45; 1.5 h, Melatonin: 47.89% ± 6.86, 17βE₂ → Melatonin: 26.98% ± 11.72) but not significantly suppressed by 17βE₂ after incubation for 2 h. GABA did not affect the percentages of motile spermatozoa, hyperactivated spermatozoa and melatonin-enhanced hyperactivation (Figs. 1C, 1D).

Estradiol consists of 17αE₂ and 17βE₂. Generally, 17αE₂ is a stereoisomer of 17βE₂ and is at least 200-fold less active as a hormone [22, 23]. After swim up, 20 ng/ml 17αE₂ was added to the mTALP medium containing motile spermatozoa. After additional incubation for 5 min, 1 nM melatonin was added to the same medium. After supplementation with 1 nM melatonin, spermatozoa were incubated for 4 h. As shown in Fig. 2, 20 ng/ml 17αE₂ did not affect the percentages of motile spermatozoa,
hyperactivated spermatozoa and melatonin-enhanced hyperactivation.

Effect of tamoxifen on suppression of melatonin-enhanced hyperactivation by $17\beta E_2$

Because melatonin-enhanced hyperactivation was suppressed by $17\beta E_2$ (Fig. 1), we examined whether the mechanism acted via the ER. In order to examine whether the ER was associated with suppression of melatonin-enhanced hyperactivation caused by $17\beta E_2$, we used tamoxifen, which is a popular ER antagonist [24-26]. It was reported that several micromoles of tamoxifen acted as an ER antagonist [27-29], although a high concentration of tamoxifen inhibited protein kinase C (PKC) in some cases [30, 31]. In a previous study [8], 1 µM tamoxifen inhibited only suppression of progesterone-enhanced hyperactivation caused by $17\beta E_2$. After swim up in the present study, 1 µM tamoxifen was added to the mTALP medium containing motile spermatozoa, and after additional incubation for 5 min, 1 nM melatonin was added to the same medium. After supplementation with 1 nM melatonin, spermatozoa were incubated for 4 h. As shown in Figs. 3A and 3B, 1 µM tamoxifen did not affect the percentages of motile spermatozoa, hyperactivated spermatozoa and melatonin-enhanced hyperactivated spermatozoa.

After swim up, 1 µM tamoxifen was added to the mTALP medium containing motile spermatozoa, and after additional incubation for 5 min, 20 ng/ml $17\beta E_2$ was added to the same medium. After additional incubation for 5 min again, 1 nM melatonin was added to the same medium. After supplementation with 1 nM melatonin, spermatozoa were incubated for 4 h. As shown in Figs. 3C and 3D, tamoxifen significantly inhibited suppression of melatonin-enhanced hyperactivation by $17\beta E_2$ after incubation for 1 or 1.5 h (1 h, Melatonin: 28.94% ± 13.64, $17\beta E_2 \rightarrow$ Melatonin: 6.01% ± 3.81,
Tamoxifen $\rightarrow$ 17$\beta$E$_2$ $\rightarrow$ Melatonin: 23.94% ± 9.52; 1.5 h, Melatonin: 67.89% ± 8.37, 17$\beta$E$_2$ $\rightarrow$ Melatonin: 34.71% ± 13.41, Tamoxifen $\rightarrow$ 17$\beta$E$_2$ $\rightarrow$ Melatonin: 62.57% ± 9.77), but it did not affect the percentage of motile spermatozoa.

Non-genomic suppression of melatonin-enhanced hyperactivation by 17$\beta$E$_2$

Because 17$\beta$E$_2$ suppresses progesterone-enhanced hyperactivation through non-genomic regulation via the membrane ER [8], we examined whether melatonin-enhanced hyperactivation was also suppressed by 17$\beta$E$_2$ through non-genomic regulation using BSA-17$\beta$E$_2$, which binds only to the membrane ER and not to the intracellular ER, thereby blocking entry of BSA-17$\beta$E$_2$ into the cell [32, 33].

After swim up, 1 µM tamoxifen was added to the mTALP medium containing motile spermatozoa, and after incubation for 5 min, 7.4 nM BSA-17$\beta$E$_2$, which is converted into approximately 20 ng/ml 17$\beta$E$_2$, was added to the medium. After additional incubation for 5 min again, 1 nM melatonin was added to the medium. After supplementation with 1 nM melatonin, spermatozoa were incubated for 4 h. As shown in Fig. 4A, BSA-17$\beta$E$_2$ did not affect the percentage of motile spermatozoa. In contrast, BSA-17$\beta$E$_2$ significantly suppressed melatonin-enhanced hyperactivation after incubation for 1, 1.5 or 2 h (1 h, Melatonin: 17.31% ± 5.42, BSA-17$\beta$E$_2$ $\rightarrow$ Melatonin: 5.82% ± 3.74; 1.5 h, Melatonin: 52.72% ± 17.39, BSA-17$\beta$E$_2$ $\rightarrow$ Melatonin: 20.06% ± 9.53; 2 h, Melatonin: 87.03% ± 6.32, BSA-17$\beta$E$_2$ $\rightarrow$ Melatonin: 58.87% ± 12.08).

Moreover, suppression of melatonin-enhanced hyperactivation by BSA-17$\beta$E$_2$ was significantly inhibited by 1 µM tamoxifen as in the case of 17$\beta$E$_2$ (1 h, Tamoxifen $\rightarrow$ BSA-17$\beta$E$_2$ $\rightarrow$ Melatonin: 18.61% ± 6.87; 1.5 h, Tamoxifen $\rightarrow$ BSA-17$\beta$E$_2$ $\rightarrow$ Melatonin: 55.11% ± 8.85; 1.5 h, Tamoxifen $\rightarrow$ BSA-17$\beta$E$_2$ $\rightarrow$ Melatonin: 87.54% ± 9.77).
Dose-dependent effect of 17βE₂ on melatonin-enhanced hyperactivation

In the next step, we examined whether 17βE₂ suppressed melatonin-enhanced hyperactivation in a dose-dependent manner (Fig. 5) because our previous studies [8, 10] reported that progesterone-enhanced hyperactivation was dose dependently suppressed by 17βE₂.

Firstly, we observed sperm movement which were beforehand exposed to estrogen (Figs. 5A and 5B). After swim up, 2 pg/ml to 20 ng/ml 17βE₂ were added to the mTALP medium containing motile spermatozoa, and after additional incubation for 5 min, 1 nM melatonin was added to the medium. After supplementation with 1 nM melatonin, spermatozoa were incubated for 4 h. As shown in Fig. 5A, 17βE₂ did not affect the percentage of motile spermatozoa at the concentration tested. By contrast, 17βE₂ significantly suppressed melatonin-enhanced hyperactivation in a dose-dependent manner (Fig. 5B). After incubation for 1 h, 200 pg/ml to 20 ng/ml 17βE₂ significantly suppressed melatonin-enhanced hyperactivation (Melatonin: 21.38% ± 3.49, 200 pg/ml 17βE₂ → Melatonin: 6.32% ± 4.22, 2 ng/ml 17βE₂ → Melatonin: 5.1% ± 4.32, 20 ng/ml 17βE₂ → Melatonin: 4.77% ± 5.06), whereas 2 pg/ml 17βE₂ did not. Moreover, the effect of 20 pg/ml 17βE₂ was also not significantly different compared with the control and melatonin (Control: 4.48% ± 4.08, Melatonin: 21.38% ± 3.49, 20 pg/ml 17βE₂ → Melatonin: 13.85% ± 6.59). After incubation for 1.5 h, 20 ng/ml 17βE₂ significantly suppressed melatonin-enhanced hyperactivation (Melatonin: 83.34% ± 2.74, 20 ng/ml 17βE₂ → Melatonin: 48.66% ± 20.79), whereas 2 pg/ml to 20 pg/ml 17βE₂ did not. The effects of 200 pg/ml and 2 ng/ml 17βE₂ were not significantly different compared...
with the control and melatonin (Control: 45.95% ± 23.47, Melatonin: 83.34% ± 2.74, 200 pg/ml 17\(\beta\)E\(_2\) → Melatonin: 58.85% ± 14.95, 2 ng/ml 17\(\beta\)E\(_2\) → Melatonin: 52.13% ± 18.52). After incubation for 2 h, 17\(\beta\)E\(_2\) did not suppress melatonin-enhanced hyperactivation.

In the next step, hamster spermatozoa were exposed to the mixture of 1 nM melatonin and 2 pg/ml to 20 ng/ml 17\(\beta\)E\(_2\) after swim up and incubated for 4 h in order to mimic the physiological action of estrogen in the spermatozoa (Figs. 5C and 5D). As shown in Fig. 5C, 17\(\beta\)E\(_2\) did not affect the percentage of motile spermatozoa. By contrast, 17\(\beta\)E\(_2\) suppressed melatonin-enhanced hyperactivation in a dose-dependent manner (Fig. 5D). After incubation for 1 h, melatonin slightly enhanced hyperactivation, but the enhancement of hyperactivation caused by melatonin was not significantly different compared with the control (Control: 9.65% ± 2.84, Melatonin: 25.87% ± 8.86). Moreover, 20 pg/ml to 20 ng/ml 17\(\beta\)E\(_2\) slightly suppressed the effect of melatonin, but the level of hyperactivation was not significantly different compared with that with melatonin only (Melatonin: 25.87% ± 8.86, Melatonin + 20 pg/ml 17\(\beta\)E\(_2\): 18.47% ± 11.8, Melatonin + 200 pg/ml 17\(\beta\)E\(_2\): 13.99% ± 7.39, Melatonin + 2 ng/ml 17\(\beta\)E\(_2\): 12.73% ± 3.57, Melatonin + 20 ng/ml 17\(\beta\)E\(_2\): 10.99% ± 6.28). After incubation for 1.5 h, 2 ng/ml and 20 ng/ml 17\(\beta\)E\(_2\) significantly suppressed melatonin-enhanced hyperactivation (Melatonin: 65.55% ± 2.98, Melatonin + 2 ng/ml 17\(\beta\)E\(_2\): 36.68% ± 9.41, Melatonin + 20 ng/ml 17\(\beta\)E\(_2\): 39.35% ± 7.56), whereas 2 pg/ml to 200 pg/ml 17\(\beta\)E\(_2\) did not. After incubation for 2 h, 17\(\beta\)E\(_2\) did not suppress melatonin-enhanced hyperactivation.

Finally, we observed sperm movement which were beforehand exposed to melatonin (Figs. 5E and 5F). Motile spermatozoa were exposed to 2 pg/ml to 20 ng/ml 17\(\beta\)E\(_2\)
after exposure to 1 nM melatonin for 5 min. After addition of 17βE₂ to the mTALP medium, spermatozoa were incubated for 4 h. As shown in Figs. 5E and 5F, 2 pg/ml to 20 ng/ml 17βE₂ did not affect the percentages of motile spermatozoa, hyperactivated spermatozoa and melatonin-enhanced hyperactivation.

**Discussion**

Under capacitation conditions, sperm hyperactivation spontaneously occurs *in vivo* and *in vitro* [1, 3, 34-36]. Spontaneous hyperactivation time-dependently occurs during capacitation processes [1, 3, 34-36]. Recent studies using human and hamster spermatozoa have shown that hyperactivation is enhanced by progesterone, melatonin and serotonin [5-7, 11-13]. Moreover, it has been also shown that progesterone-enhanced hyperactivation of hamster spermatozoa is suppressed by 17βE₂ and GABA [8, 10, 18]. Steroids of these hormones, such as progesterone and 17βE₂, regulate sperm hyperactivation via non-genomic regulation [2, 7, 8, 37]. In genomic regulation, generally, steroids bind to an intracellular receptor and induce gene expression, whereas in non-genomic regulation, the steroids bind to a membrane receptor and increase the concentration of a second messenger such as Ca²⁺ and/or cAMP [7, 9, 37]. In order to examine whether the regulatory effects of steroids are non-genomic, a BSA-conjugated steroid was used in both previous studies [7, 8, 18] and in the present study (Fig. 4). Because BSA blocks entry of a BSA-conjugated steroid into the cell, the steroid is unable to bind to the intracellular receptor but can bind to the membrane receptor [32, 33]. Therefore, it follows that the effects of a BSA-conjugated steroid will occur through non-genomic regulation. The results obtained from the present study (Fig. 4) suggest that enhancement of hyperactivation by
melatonin was suppressed by 17βE₂ through non-genomic regulation via a membrane ER.

Progesterone regulates hyperactivation through non-genomic regulation associated with two types of Ca²⁺ signaling: Ca²⁺ influx and release of Ca²⁺ from the Ca²⁺ store [2, 7, 36-40]. Ca²⁺ influx is induced by progesterone through the CatSper, which is a sperm-specific Ca²⁺ channel located in the principal piece of the flagellum [41, 42]. The release of Ca²⁺ from the Ca²⁺ store by progesterone is associated with both the PR and PLC [7]. Activation of PLC produces IP₃ and diacylglycerol (DAG) from phosphatidylcholine and/or phosphatidylinositol. IP₃ releases Ca²⁺ from the IP₃R-gated Ca²⁺ store localized at the base of flagellum [36-40]. Ca²⁺ and DAG regulate hyperactivation through activation of calmodulin-dependent protein kinase II and PKC [9, 43]. After Ca²⁺ signaling is stimulated by progesterone, many tyrosine phosphorylations, especially the 80- and 85-kDa tyrosine phosphorylations of the fibrous sheath (FS), are increased and enhanced [7, 8, 36]. The 80- and 85kDa tyrosine phosphorylated FS proteins were identified as the A-kinase anchoring protein, which is a major component of the FS [44]. In general, tyrosine phosphorylation is a very important event during capacitation/hyperactivation [1, 2, 45-47]. It has been suggested that the 80- and 85-kDa tyrosine phosphorylations of the FS are closely associated with capacitation/hyperactivation [19, 46, 48]; and regulated by Ca²⁺/calmodulin-dependent signals [49] and protein phosphatase 1 [50]. In non-genomic regulation, progesterone also activates adenylate cyclase to increase the cAMP concentration [37, 51, 52]. cAMP is an essential molecule for hyperactivation; and regulates the tyrosine phosphorylations, especially the 80- and 85-kDa tyrosine phosphorylations of the FS, through protein kinase A (PKA) signals [1, 45, 47].
Moreover, progesterone enhances hyperactivation through cAMP–PKA signals [9]. In contrast, 17βE₂ suppresses progesterone-enhanced hyperactivation through non-genomic regulation associated with the ER and tyrosine dephosphorylations except for the 80- and 85-kDa tyrosine phosphorylations of the FS [8]. GABA also suppresses progesterone-enhanced hyperactivation via the GABAₐ receptor [18]. However, the regulatory mechanisms associated with suppression of progesterone-enhanced hyperactivation by 17βE₂ and GABA are still unclear.

It has been shown that melatonin enhances hyperactivation of hamster spermatozoa via MT1 [11]. Moreover, in ram and human spermatozoa, it has been shown that melatonin increases sperm quality, motility, capacitation, fertility rate and the activities of antioxidant enzymes, and decreases nitric oxide (NO) [12, 53-56]. NO at low concentrations increases capacitation through a mitogen-activated protein kinase cascade and tyrosine phosphorylation, especially the 80- and 85-kDa tyrosine phosphorylations of the FS, [57-59], whereas at high concentrations, it negatively affects sperm function [58, 60].

It has been shown that progesterone and 17βE₂ bind to the head of hamster spermatozoa [7, 8], but it has not been shown where melatonin binds [11]. Ram spermatozoa have two melatonin receptors (MT1 and MT2), which are localized at various sites [61]. In humans, the MT1 receptor is located in the equatorial region of the sperm head [62]. In the present study, we did not show the regulatory mechanism of sperm hyperactivation caused by melatonin and 17βE₂. One of the possibilities is the suppression of binding of melatonin to the melatonin receptor by 17βE₂. Another is the suppression of intracellular melatonin signals by 17βE₂. In a study investigating the regulation of sperm hyperactivation caused by progesterone and 17βE₂, neither
steroid interfered with binding to their respective receptors [8]. In contrast, one of the intracellular progesterone signal, such as tyrosine phosphorylation, was suppressed by 17βE2 [8]. We expect that 17βE2 affects intracellular melatonin signals in a manner similar to the regulatory mechanism of progesterone and 17βE2 because we previously noted that melatonin enhanced sperm hyperactivation through enhancement of tyrosine phosphorylations [11]. In future studies, we will show the detailed interaction between melatonin and 17βE2.

Progesterone enhances hamster sperm hyperactivation in a dose-dependent manner [7], and progesterone-enhanced hyperactivation is dose-dependently suppressed by 17βE2 and GABA [8, 10, 18]. The concentrations of progesterone and 17βE2 in blood and tissues fluctuate in association with the estrous or menstrual cycle [63]. The concentration of GABA in the female genital tract also fluctuates in association with the estrous cycle [64]. Therefore, we previously proposed that hamster sperm hyperactivation was regulated by balances among the concentrations of progesterone, 17βE2 and GABA [8, 10, 18]. Additionally, picomole or higher concentrations of melatonin enhance hamster sperm hyperactivation [11]. It was reported that picomole or higher concentrations of melatonin were detected from the follicular fluid of humans [65, 66]. Based on these reports, we tried to examine the interactions among melatonin, 17βE2 and GABA; in the present study and found that 17βE2 suppressed melatonin-enhanced hyperactivation in a dose-dependent manner, whereas GABA did not (Figs. 1, 4, 5). 17βE2 suppressed melatonin-enhanced hyperactivation through non-genomic regulation via the ER (Figs. 3, 4). In another recent study [13], it was reported that serotonin also enhanced hamster sperm hyperactivation. These results and results of previous studies [7, 8, 10, 11, 13, 18] suggest that in the hamster,
progesterone, melatonin and serotonin act as enhancers of hyperactivation; and that
17βE₂ and GABA act as suppressors. Although we did not investigate relationships
among the regulation by progesterone, 17βE₂ and GABA, the regulation by melatonin
and 17βE₂ and the regulation by serotonin, we propose that materials in the follicular
fluid, such as progesterone, melatonin, serotonin, 17βE₂ and GABA, regulate
hyperactivation of hamster spermatozoa.

It has been suggested that spermatozoa are capacitated/hyperactivated in response to
changes in the environment of the oviduct [7, 8, 10, 11, 13, 18, 35]. During
capacitation/hyperactivation of hamster spermatozoa, progesterone, melatonin and
serotonin act as enhancers and 17βE₂, and GABA acts as a suppressor [7, 8, 10, 11, 13,
18]. Although GABA acts as a suppressor of hamster spermatozoa [18], it is an
enhancer of other mammalian spermatozoa such as those of humans, rams and rats
[14-17]. Because the concentrations of hormones vary during the female’s estrous
cycle [63], it seems that mammalian spermatozoa are capacitated/hyperactivated in
response to the changing environment of the oviduct [8, 10, 18, 35]. In particular, the
results of the present study suggest that mammalian spermatozoa, at least, hamster
spermatozoa, are capacitated/hyperactivated according to changing concentrations of
melatonin and 17βE₂ in the oviduct.

There are two regulatory mechanisms of hyperactivation in mammalian or at least
hamster spermatozoa. One is a spontaneous regulatory mechanism associated with
Ca²⁺, HCO₃⁻, protein phosphorylations and so on [1-3, 45, 47]. Another is a
ligand-dependent modulatory mechanism associated with progesterone, 17βE₂,
melatonin, serotonin and GABA [7-11, 13, 18] (Fig. 1). In both mechanisms, Ca²⁺
signals, cAMP–PKA signals and tyrosine phosphorylations are very important [1-3, 7-9,
However, the ligand-dependent modulatory mechanism differs from the spontaneous regulatory mechanism because hyperactivation itself is not suppressed by inhibition of the ligand-dependent modulatory mechanism [7-9, 11, 13, 18] (Fig. 1).

In conclusion, we propose that spermatozoa start to be capacitated/hyperactivated through the spontaneous regulatory mechanism in the oviduct. After that, it seems that capacitation/hyperactivation of spermatozoa is enhanced through a modulatory mechanism associated with changes in the environment of the oviduct.

**Declaration of interest**

The authors declare that they have no conflict of interest that could be perceived as prejudicing the impartiality of the presented research.

**Funding**

This research did not receive any grant from any funding agency in the public, commercial or not-for-profit sector.
References


17. **Jin J-Y, Chen W-Y, Zhou CX, Chen Z-H, Yuan Y-Y, Ni Y, Chan HC, Shi Q-X.** Activation of GABA\textsubscript{A} receptor/Cl\textsuperscript{−} channel and capacitation in rat spermatozoa: HCO\textsubscript{3}\textsuperscript{−} and Cl\textsuperscript{−} are essential. *Syst Biol Reprod Med* 2009; **55**: 97–108.


19. **Fujinoki M, Suzuki T, Takayama T, Shibahara H, Ohtake H.** Profiling of


27. Daniel P, Gaskell SJ, Bishop H, Nicholson RI. Determination of tamoxifen and


37. **Baldi E, Luconi M, Muratori M, Marchiani S, Tamburrino L, Forti G.**

38. **Ho HC, Granish KA, Suarez SS.** Hyperactivated motility of bull sperm is triggered at the axoneme by Ca\(^{2+}\) and not cAMP. *Dev Biol* 2002; **250**: 208–217.

39. **Ho HC, Suarez SS.** An inositol 1,4,5-trisphosphate receptor-gated intracellular Ca\(^{2+}\) store is involved in regulating sperm hyperactivated motility. *Biol Reprod* 2001; **65**: 1606–1616.

40. **Ho HC, Suarez SS.** Characterization of the intracellular calcium store at the base of the sperm flagellum that regulates hyperactivated motility. *Biol Reprod* 2003; **68**: 1590–1596.


46. **Visconti PE, Bailey JL, Moore GD, Pan D, Old-Clarke P, Kopf GS.** Capacitation of mouse spermatozoa I. Correlation between the capacitation state


54. Espino J, Bejarano I, Ortiz A, Lozano GM, García JF, Pariente JA, Rodríguez AB. Melatonin as a potential tool against oxidative damage and apoptosis in...


63. Schillo KK. Reproductive Physiology of Mammals: From Farm to Field and Beyond. New York: Delmar; 2009.


Figure Legends

Figure 1 Suppression of melatonin-enhanced hyperactivation by $17\beta$E$_2$ and GABA. The percentages of motile (A, C) and hyperactivated (B, D) spermatozoa are shown for when spermatozoa were exposed to melatonin and $17\beta$E$_2$ (A, B) or GABA (C, D). After swim up, $17\beta$E$_2$, GABA or vehicle was added to the mTALP medium containing motile spermatozoa. After incubation for 5 min, melatonin or vehicle was added to the same medium. Data are expressed as the mean ± SD. (A, B) (Control): mTALP medium with 0.2% (v/v) EtOH; (Melatonin): mTALP medium with addition of 1 nM melatonin and 0.2% (v/v) EtOH; ($17\beta$E$_2 \rightarrow$ Melatonin): mTALP medium with addition of 1 nM melatonin, 20 ng/ml $17\beta$E$_2$ and 0.2% (v/v) EtOH. (C, D) (Control): mTALP medium with 0.1% (v/v) EtOH; (Melatonin): mTALP medium with addition of 1 nM melatonin and 0.1% (v/v) EtOH; (GABA $\rightarrow$ Melatonin): mTALP medium with addition of 1 nM melatonin, 5 µM GABA and 0.1% (v/v) EtOH. *Significant difference compared with “Control” and “$17\beta$E$_2 \rightarrow$ Melatonin” (P<0.05). **Significant difference compared with “Control” (P<0.05). GABA, γ-aminobutyric acid; $17\beta$E$_2$, 17β-estradiol; EtOH, ethanol; mTALP medium, modified Tyrode’s albumin lactate pyruvate medium.

Figure 2 Effect of $17\alpha$E$_2$ on melatonin-enhanced hyperactivation. The percentages of motile (A) and hyperactivated (B) spermatozoa are shown for when spermatozoa were exposed to melatonin and $17\alpha$E$_2$. After swim up, $17\alpha$E$_2$ or vehicle was added to the mTALP medium containing motile spermatozoa. After incubation for 5 min, melatonin or vehicle was added to the same medium. Data are expressed as the mean ± SD. (Control): mTALP medium with 0.2% (v/v) EtOH; (Melatonin): mTALP medium with addition of 1 nM melatonin and 0.2% (v/v) EtOH; ($17\alpha$E$_2 \rightarrow$ Melatonin): mTALP medium with addition of 1 nM $17\alpha$E$_2$ and 0.2% (v/v) EtOH. *Significant difference compared with “Control” and “$17\alpha$E$_2 \rightarrow$ Melatonin” (P<0.05). **Significant difference compared with “Control” (P<0.05). GABA, γ-aminobutyric acid; $17\alpha$E$_2$, 17α-estradiol; EtOH, ethanol; mTALP medium, modified Tyrode’s albumin lactate pyruvate medium.
medium with 1 nM melatonin and 0.2% (v/v) EtOH; (17αE2): mTALP medium with 20 ng/ml 17αE2 and 0.2% (v/v) EtOH; (17αE2 → Melatonin): mTALP medium with 1 nM melatonin, 20 ng/ml 17αE2 and 0.2% (v/v) EtOH. *Significant difference compared with “Control” and “17αE2” (P<0.05). 17αE2, 17α-estradiol; EtOH, ethanol; mTALP medium, modified Tyrode’s albumin lactate pyruvate medium.

Figure 3 Inhibition of suppression of melatonin-enhanced hyperactivation by 17βE2.

The percentages of motile (A, C) and hyperactivated (B, D) spermatozoa are shown (A, B) for when spermatozoa were exposed to melatonin and tamoxifen, and (C, D) for when spermatozoa were exposed to melatonin, 17βE2 and tamoxifen. In A and B, after swim up, tamoxifen or vehicle was added to the mTALP medium containing motile spermatozoa. After incubation for 5 min, melatonin or vehicle was added to the same medium. In C and D, after swim up, tamoxifen or vehicle was added to the mTALP medium containing motile spermatozoa. After incubation for 5 min, 17βE2 or vehicle was added to the same medium. After incubation for 5 min again, melatonin or vehicle was added to the same medium. Data are expressed as the mean ± SD. (A, B) (Control): mTALP medium with 0.1% (v/v) EtOH and 0.1% (v/v) DMSO; (Melatonin): mTALP medium with addition of 1 nM melatonin, 0.1% (v/v) EtOH and 0.1% (v/v) DMSO; (Tamoxifen → Melatonin): mTALP medium with addition of 1 nM melatonin, 1 µM tamoxifen, 0.1% (v/v) EtOH and 0.1% (v/v) DMSO. (C, D) (Control): mTALP medium with 0.2% (v/v) EtOH and 0.1% (v/v) DMSO; (Melatonin): mTALP medium with addition of 1 nM melatonin, 0.2% (v/v) EtOH and 0.1% (v/v) DMSO; (17βE2 → Melatonin): mTALP medium with addition of 1 nM melatonin, 20 ng/ml 17βE2, 0.2% (v/v) EtOH and 0.1% (v/v) DMSO; (Tamoxifen → 17βE2
→Melatonin): mTALP medium with addition of 1 nM melatonin, 20 ng/ml 17βE₂, 1 μM tamoxifen, 0.2% (v/v) EtOH and 0.1% (v/v) DMSO. *Significant difference compared with “Control” (P<0.05). **Significant difference compared with “Control” and “17βE₂ → Melatonin” (P<0.05). DMSO, dimethyl sulfoxide; 17βE₂, 17β-estradiol; EtOH, ethanol; mTALP medium, modified Tyrode’s albumin lactate pyruvate medium.

Figure 4 Non-genomic suppression of melatonin-enhanced hyperactivation by 17βE₂.

The percentages of motile (A) and hyperactivated (B) spermatozoa are shown for when spermatozoa were exposed to melatonin, BSA-17βE₂ and tamoxifen. After swim up, tamoxifen or vehicle was added to the mTALP medium containing motile spermatozoa. After incubation for 5 min, BSA-17βE₂ or vehicle was added to the same medium. After incubation for 5 min again, melatonin or vehicle was added to the same medium.

Data are expressed as the mean ± SD. (Control): mTALP medium with 0.1% (v/v) EtOH and 0.1% (v/v) DMSO; (Melatonin): mTALP medium with addition of 1 nM melatonin, 0.1% (v/v) EtOH and 0.1% (v/v) DMSO; (BSA-17βE₂ → Melatonin): mTALP medium with addition of 1 nM melatonin, 7.4 nM BSA-17βE₂, 0.1% (v/v) EtOH and 0.1% (v/v) DMSO; (Tamoxifen → BSA-17βE₂ → Melatonin): mTALP medium with addition of 1 nM melatonin, 7.4 nM BSA-17βE₂, 1 μM tamoxifen, 0.1% (v/v) EtOH and 0.1% (v/v) DMSO. *Significant difference compared with “Control” and “BSA-17βE₂ → Melatonin” (P<0.05). DMSO, dimethyl sulfoxide; 17βE₂, 17β-estradiol; EtOH, ethanol; BSA-17βE₂, fluorescein isothiocyanate and bovine serum albumin (BSA)-conjugated 17βE₂; mTALP medium, modified Tyrode’s albumin lactate pyruvate medium.
Figure 5 Dose-dependent effects of 17βE<sub>2</sub> on melatonin-enhanced hyperactivation. The percentages of motile (A, C, E) and hyperactivated (B, D, F) spermatozoa are shown (A, B) for when spermatozoa were exposed to melatonin after exposure to 17βE<sub>2</sub>, (C, D) for when spermatozoa were simultaneously exposed to melatonin and 17βE<sub>2</sub>, and (E, F) for when spermatozoa were exposed to melatonin before exposure to 17βE<sub>2</sub>. In A and B, after swim up, 17βE<sub>2</sub> or vehicle was added to the mTALP medium containing motile spermatozoa. After incubation for 5 min, melatonin or vehicle was added to the same medium. In C and D, after swim up, mixtures of melatonin and 17βE<sub>2</sub> or vehicle were added to the mTALP medium containing motile spermatozoa. In E and F, after swim up, melatonin or vehicle was added to the mTALP medium containing motile spermatozoa. After incubation for 5 min, 17βE<sub>2</sub> or vehicle was added to the same medium. Data are expressed as the mean ± SD. (Control): mTALP medium with 0.2% (v/v) EtOH; (Melatonin): mTALP medium with added 1 nM melatonin and 0.2% (v/v) EtOH; (20 ng/ml 17βE<sub>2</sub> → Melatonin, Melatonin + 20 ng/ml 17βE<sub>2</sub> or Melatonin → 20 ng/ml 17βE<sub>2</sub>): mTALP medium with addition of 1 nM melatonin, 20 ng/ml 17βE<sub>2</sub> and 0.2% (v/v) EtOH; (2 ng/ml 17βE<sub>2</sub> → Melatonin, Melatonin + 2 ng/ml 17βE<sub>2</sub> or Melatonin → 2 ng/ml 17βE<sub>2</sub>): mTALP medium with addition of 1 nM melatonin, 2 ng/ml 17βE<sub>2</sub> and 0.2% (v/v) EtOH; (200 pg/ml 17βE<sub>2</sub> → Melatonin, Melatonin + 200 pg/ml 17βE<sub>2</sub> or Melatonin → 200 pg/ml 17βE<sub>2</sub>): mTALP medium with addition of 1 nM melatonin, 200 pg/ml 17βE<sub>2</sub> and 0.2% (v/v) EtOH; (20 pg/ml 17βE<sub>2</sub> → Melatonin, Melatonin + 20 pg/ml 17βE<sub>2</sub> or Melatonin → 20 pg/ml 17βE<sub>2</sub>): mTALP medium with addition of 1 nM melatonin, 20 pg/ml 17βE<sub>2</sub> and 0.2% (v/v) EtOH; (2 pg/ml 17βE<sub>2</sub> → Melatonin, Melatonin + 2 pg/ml 17βE<sub>2</sub> or Melatonin → 2 pg/ml 17βE<sub>2</sub>): mTALP medium with addition of 1 nM melatonin, 2 pg/ml 17βE<sub>2</sub> and 0.2% (v/v) EtOH.
*Significant difference compared with “Control” (P<0.05).  §Significant difference compared with “Melatonin” (P<0.05).  Items with significant differences are indicated by symbols in the same color.  17βE2, 17β-estradiol; EtOH, ethanol; mTALP medium, modified Tyrode’s albumin lactate pyruvate medium.
Figure 1
Figure 2
Figure 3
Figure 4